Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3174_Библиотеки_им_академика_М_И_Перельмана
.pdf
280
165. Bateman A., Fonagy P. Treatment of Borderline Personality Disorder With Psychoan-
alytically Oriented Partial Hospitalization: An 18–Month Follow-Up. Am J Psychiatry.
2001;158:36–42.
166. Beckham J.C., Moore S.D., Feldman M.E. et al. Health Status, Somatization, and Se-
verity of Posttraumatic Stress Disorder in Vietnam Combat Veterans With Posttraumatic
Stress Disorder. Am J Psychiatry. 1998; 155:1565–9.
167. Bisson J., Andrew M. Psychological treatment of post-traumatic stress disorder
(PTSD). The Cochrane Database of Systematic Reviews 2007 Issue 3.
168. Blondell R.D., Frierson R.L., Lippmann S.B. Alcoholism. Taking a preventive, public
health approach. Postgraduate Medicine. 1999;100:1.
169. Blumenthal J.A., Babyak M.A., Doraiswamy P.M. et al. Exercise and Pharmacothera-
py in the Treatment of Major Depressive Disorder. Psychosom Med. 2007;69:587–96.
170. Borys D.J., Setzer S.C., Ling L.J., Reisdorf J. et al. Acute fluoxetine overdose: a re-
port of 234 cases. Am J Emerg Med. 1992;10:115–20.
171. Boscarino JA, Adams RE. PTSD onset and course following the World Trade Center
disaster: findings and implications for future research. Soc Psychiatry Psychiatr Epidemi-
ol. 2009 Mar 7.
172. Brewin C.R., Andrews B., Rose S., Kirk M. Acute Stress Disorder and Posttraumatic
Stress Disorder in Victims of Violent Crime. Am J Psychiatry. 1999;156:360–6.
173. Bringager C.B., Gauer K., Arnesen H. et al. Nonfearful Panic Disorder in Chest-Pain
Patients: Status After Nine-Year Follow-Up. Psychosomatics. 2008;49:426–37.
174. Bruce T.J., Saeed S.A. Social Anxiety Disorder: A Common, Underrecognized Mental
Disorder. Am Fam Physician. 1999;60:2311–22.
175. Bryant R.A., Mastrodomenico J., Felmingham K.L. et al. Treatment of Acute Stress
Disorder: A Randomized Controlled Trial. Arch Gen Psychiatry. 2008;65:659–67.
176. Burge S.K., Schneider F.D. Alcohol-Related Problems: Recognition and Intervention.
Am Fam Phys. 1999;59(2):361–72.
177. Caetano R., Clark C.L., Greenfield T.K. Prevalence, Trends and Incidence of Alcohol
Withdral Symptoms. Alcohol Health&Research World. 1998;22:1:73–80.
178. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking ces-
sation. The Cochrane Database of Systematic Reviews 2008 Issue 3.
179. Caponnetto P., Polosa R., Russo C. et al. Successful smoking cessation with elec-
tronic cigarettes in smokers with a documented history of recurring relapses: a case se-
ries. J Med Case Reports. 2011;5(1):585.
180. Carroll K.M., Ball S.A., Nich C. et al. Targeting Behavioral Therapies to Enhance Nal-
trexone Treatment of Opioid Dependence. Arch Gen Psychiatry. 2001;58:755–61.
181. Cavanaugh S.A., Furlanetto L.M., Creech S.D., Powell L.H. Medical Illness, Past De-
pression, and Present Depression: A Predictive Triad for In-Hospital Mortality. Am J Psy-
chiatry. 2001;158:43–8.
182. Chapman L.F. Experimental induction of hangover. Q J Stud Alcohol. 1970;5(Suppl
5):67–86.
183. Cigarette Smoking Among Adults-United States, 2007. JAMA. 2009;301(4):373–5.
184. Cipriani A., La Ferla T., Furukawa T.A. et al. Sertraline versus other antidepressive
agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 2.
185. Cipriani A., Barbui C., Salanti G. et al. Comparative efficacy and acceptability of anti-
manic drugs in acute mania: a multiple-treatments meta-analysis. Lancet.
2011;378:1306–15.
186. Clair C., Rigotti N.A., Porneala B. et al. Association of smoking cessation and weight
change with cardiovascular disease among adults with and without diabetes. JAMA.
2013; 309:1014–21.
187. Clark D.M., Salkovskis P.M., Hackmann A. et al. Brief Cognitive Therapy for Panic
Disorder: A Randomized Controlled Trial. J Consult Clin Psychol. 1999;67:583–9.
188. Cornelius J.R., Salloum I.M., Ehler J.G. et al. Fluoxetine in depressed alcoholics: A
double-blind, placebo-controlled trial. Arch Gen Psych. 1997;54:700–5.
281
189. Coryell W., Fiedorowicz J.G., Solomon D. et al. Effects of anxiety on the long-term
course of depressive disorders. Br J Psychiatry. 2012;200(3):210–5.
190. Cuijpers P., van Straten A., Smit F. et al. Preventing the Onset of Depressive Disor-
ders: A Meta-Analytic Review of Psychological Interventions. Am J Psychiatry.
2008;165:1272–80.
191. Davies S.J.C., Ghahramani P., Jackson P.R. et al. Association of panic disorder and
panic attacks with hypertension. Am J Med. 1999:107:310–6.
192. Daughton D.M., Fortmann S.P., Glover E.D. et al. The Smoking Cessation Efficacy of
Varying Doses of Nicotine Patch Delivery Systems 4 To 5 Years Post-Quit Day. Prev
Med. 1999;28(2):113–8.
193. de Jong J.T.V.M., Komproe I.H., Van Ommeren M. et al. Lifetime Events and Post-
traumatic Stress Disorder in 4 Postconflict Settings. JAMA. 2001;286:555–62.
194. Dimidjian S., Hollon S.D., Dobson K.S. et al. Randomized trial of behavioral activa-
tion, cognitive therapy, and antidepressant medication in the acute treatment of adults
with major depression. J Consult Clin Psychol. 2006;74(4):658–70.
195. Dobson K.S., Hollon S.D., Dimidjian S. et al. Randomized trial of behavioral activa-
tion, cognitive therapy, and antidepressant medication in the prevention of relapse and
recurrence in major depression. J Consult Clin Psychol. 2008;76(3):468–77.
196. Domschke K., Kirchhof P., Zwanzger P. et al. Coincidence of paroxysmal supra-
ventricular tachycardia and panic disorder: two case reports. Ann Gen Psychiatry.
2010;9:13.
197. Eaton W.W., Shao H., Nestadt G. et al. Population-Based Study of First Onset and
Chronicity in Major Depressive Disorder. Arch Gen Psychiatry. 2008;65:513–20.
198. Ebbert J.O., Hatsukami D.K., Croghan I.T. et al. Combination Varenicline and Bu-
propion SR for Tobacco-Dependence Treatment in Cigarette Smokers: A Randomized
Trial. JAMA. 2014;311(2):155–63.
199. ECNP/EBC. The size and burden of mental disorders and other disorders of the brain
in Europe 2010. European Neuropsychopharmacology. 2011;21:655–79.
200. Fazel S., Danesh J. Serious mental disorder in 23000 prisoners: a systematic review
of 62 surveys. Lancet. 2002; 359: 545–50.
201. Feldman E., Mayou R., Hawton K. et al. Psychiatric disorder in medical inpatients. Q
J Med. 1987;63:405–12.
202. Fiellin D.A., Reid C., O'Connor P.G. Outpatient Management of Patients with Alcohol
Problems. Ann Intern Med. 2000;133:815–27.
203. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008
Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Hu-
man Services. Public Health Service. May 2008.
204. Foa E.B., Davidson J.R.T., Frances A. eds. The Expert Consensus Guideline Series:
Treatment of Posttraumatic Stress Disorder. J Clin Psychiatry. 1999;60 (suppl 16).
205. Frazier J.A. Limited Evidence for Use of Second-generation Antipsychotics in Anxiety
Disorders. Evid Based Ment Health. 2011;14(3):76.
206. Freedman S.A., Brandes D., Peri T., Shalev A. Predictors of chronic post–traumatic
stress disorder. A prospective study. British Journal of Psychiatry. 1999;174:353–359.
207. Fuller R.K., Hiller-Sturmhofel S. Alcoholism Treatment in the United States. An Over-
view. Alcohol Health&Research World. 1999;23:2:69–77.
208. Furukawa T.A., McGuire H., Barbui C. Meta-analysis of effects and side effects of low
dosage tricyclic antidepressants in depression: systematic review. BMJ. 2002;325:991.
209. Furukawa T., McGuire H., Barbui C. Low dosage tricyclic antidepressants for depres-
sion. The Cochrane Database of Systematic Reviews 2003, Issue 3.
210. Furukawa T.A., Watanabe N., Churchill R. Combined psychotherapy plus antidepres-
sants for panic disorder with or without agoraphobia. The Cochrane Database of Sys-
tematic Reviews 2007, Issue 1.
211. Gallo J.J., Rabins P.V. Depression Without Sadness: Alternative Presentations of
Depression in Late Life. Am Fam Physician. 1999;60:820–6.
282
212. Garbutt J.C., West S.L., Carey T.S. et al. Pharmacological Treatment of Alcohol De-
pendence. JAMA. 1999;281:1318–25.
213. Garbutt J., Kranzler H., O'Malley S.S. et al. Efficacy and tolerability of long-acting in-
jectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA.
2005;293:1617–25.
214. Gartlehner G., Hansen R.A., Morgan L.C. et al. Comparative Benefits and Harms of
Second-Generation Antidepressants for Treating Major Depressive Disorder. Ann Intern
Med 2011;155(11):772–85.
215. Gaster B., Holroyd J. St John's Wort for Depression. A Systematic Review. Arch In-
tern Med. 2000;160:152–6.
216. Geddes J.R., Freemantle N., Mason J. et al. Selective serotonin reuptake inhibitors
(SSRIs) versus other antidepressants for depression. The Cochrane Database of Sys-
tematic Reviews 2006, Issue 2
217. George M.S., Lydiard R.B. Social phobia secondary to physical disability. A review of
benign essential tremor (BET) and stuttering. Psychosomatics. 1994;35:520–3.
218. Gibbons R.D., Hur K., Brown C.H. et al. Benefits From Antidepressants: Synthesis of
6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized
Trials of Fluoxetine and Venlafaxine. Arch Gen Psych. 2012;69:572–9.
219. Glick I.D., Suppes T., DeBattista C. et al. Psychopharmacologic Treatment Strategies
for Depression, Bipolar Disorder, and Schizophrenia. Ann Intern Med. 2001;134:47–60.
220. Goldberg I.J., Mosca L., Piano M.R., Fisher E.A. Wine and Your Heart. AHA Medi-
cal/Scientific Statement. Circulation. 2001;103:472.
221. Gothe C.J., Molin C., Nilsson C.G. The environmental somatization syndrome. Psy-
chosomatics. 1995; 36:1–11.
222. Gowing L., Ali R., White J.M. Buprenorphine for the management of opioid withdraw-
al. Cochrane Database of Systematic Reviews 2009, Issue 3.
223. Gries C.J., Engelberg R.A., Kross E.K. et al. Predictors of Symptoms of Posttraumatic
Stress and Depression in Family Members After Patient Death in the ICU. Chest.
2010;137(2):280–7.
224. Haetherton T.F., Kozlowski L.T., Frecker R.C., Fagestrom K.O. The Fagestrom Test
for Nicotine Dependence: a revision of the Fagestrom Questionnaire. Br J Addict.
1991;86:1119–27.
225. Hajek P., West R., Foulds J. et al. Randomized Comparative Trial of Nicotine Polacri-
lex, a Transdermal Patch, Nasal Spray, and an Inhaler. Arch Intern Med.
1999;159:2033–8.
226. Hasin D., Liu X., Nunes E. et al. Effects of Major Depression on Remission and Re-
lapse of Substance Dependence. Arch Gen Psychiatry. 2002;59:375–80.
227. Hasin D.S., Stinson F.S., Ogburn E. et al. Prevalence, Correlates, Disability, and
Comorbidity of DSM-IV Alcohol Abuse and Dependence in the United States. Arch Gen
Psychiatry. 2007;64:830–42.
228. Hayashida M. An Overview of Outpatient and Inpatient Detoxification. Alcohol Health
& Research World. 1998;22:1:44–6.
229. Henri-Jean A., Amanda F., Deborah L. et al. Weight gain in smokers after quitting
cigarettes: meta-analysis. BMJ. 2012;345.
230. Hepp U., Moergeli H., Buchi S. et al. Post-traumatic stress disorder in serious acci-
dental injury: 3-year follow-up study. Br J Psychiatry. 2008;192:376–83.
231. Herring M.P., Puetz T.W., O'Connor P.J. et al. Effect of Exercise Training on Depres-
sive Symptoms Among Patients With a Chronic Illness: A Systematic Review and Meta-
analysis of Randomized Controlled Trials. Arch Intern Med. 2012;172(2):101–11.
232. Hoffman B.M., Babyak M.A., Craighead W.E. et al. Exercise and Pharmacotherapy in
Patients With Major Depression: One-Year Follow-Up of the SMILE Study. Psychosom
Med. 2011;73 (2):127–33.
233. Holford T.R., Meza R., Warner K.E. et al. Tobacco Control and the Reduction in
Smoking-Related Premature Deaths in the United States, 1964-2012. JAMA.
2014;311(2):164–71.
283
234. Hölzel L., Härter M., Reese C., Kriston L. Risk factors for chronic depression — a sys-
tematic review. J Affect Disord. 2011;129(1–3):1–13.
235. Horowitz M.J., Siegel B., Holen A. et al. Diagnostic criteria for complicated grief disor-
der. Am J Psychiatry. 1997; 154:904–10.
236. Huang Y., Kotov R., de Girolamo G. et al. DSM-IV personality disorders in the WHO
World Mental Health Surveys. Br J Psychiatry. 2009;195(1):46–53.
237. Hughes J.R., Goldstein M.G., Hurt R.D., Shiffman S. Recent Advances in the Phar-
macotherapy of Smoking. JAMA. 1999;281:72–6.
238. Hughes J.R., Stead L.F., Lancaster T. Antidepressants for smoking cessation.
Cochrane Database of Systematic Reviews 2009, Issue 3.
239. Hunot V., Churchill R., Silva de Lima M., Teixeira V. Psychological therapies for gen-
eralised anxiety disorder. The Cochrane Database of Systematic Reviews. 2007, Issue
1.
240. Jacobs D.R., Adachi H., Mulder I. et al. Cigarette Smoking and Mortality Risk.Twenty-
five-Year Follow-up of the Seven Countries Study. Arch Intern Med. 1999;159:733–40.
241. Jellinek E. Disease concept of alcoholism. 1960.
242. Johnson B.A., Rosenthal N., Capece J.A. et al. Topiramate for Treating Alcohol De-
pendence: A Randomized Controlled Trial. JAMA. 2007;298:1641–51.
243. Johnson B.A., Rosenthal N., Capece J.A. et al. Improvement of Physical Health and
Quality of Life of Alcohol-Dependent Individuals With Topiramate Treatment: US Multisite
Randomized Controlled Trial. Arch Intern Med. 2008;168:1188–99.
244. Johnson B.A., Ait-Daoud N., Wang X. et al. Topiramate for the Treatment of Cocaine
Addiction: A Randomized Clinical Trial. JAMA Psychiatry. 2013;70(12):1338–46.
245. Jonas D.E., Amick H.R., Feltner C. et al. Pharmacotherapy for Adults With Alcohol
Use Disorders in Outpatient Settings: A Systematic Review and Meta-analysis. JAMA.
2014;311(18):1889–900.
246. Jorenby D.E., Leischow S.J., Nides M.A. et al. A Controlled Trial of Sustained-
Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation. N Engl J Med.
1999;340:685–91.
247. Kathol R.G., Wenzel R.P. Natural history of symptoms of depression and anxiety dur-
ing inpatient treatment on general medicine wards. J Gen Intern Med. 1992;7:287–93.
248. Katon W., Kleinman A., Rosen G. Depression and somatization: a review. Part I. Am
J Med. 1982;72:127–35.
249. Kendler K.S., Karkowski L.M., Prescott C.A. Causal Relationship Between Stressful
Life Events and the Onset of Major Depression. Am J Psychiatry. 1999;156:837–41.
250. Kessing L.V. Severity of depressive episodes during the course of depressive disor-
der. Br J Psychiatry. 2008;192:290–3.
251. Kessler R.C., Chiu W.T., Jin R. et al. The Epidemiology of Panic Attacks, Panic Dis-
order, and Agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psy-
chiatry. 2006;63:415–24.
252. Kessler D. Lewis G., Kaur S. et al. Therapist-delivered internet psychotherapy for de-
pression in primary care: a randomised controlled trial. Lancet. 2009;374:628–34.
253. Keyes K.M., Pratt C., Galea S. et al. The burden of loss: unexpected death of a loved
one and psychiatric disorders across the life course in a national study. Am J Psychiatry.
2014;171(8):864–71.
254. Kiefer F., Jahn H., Tarnaske T. et al. Comparing and Combining Naltrexone and
Acamprosate in Relapse Prevention of Alcoholism. Arch Gen Psychiatry. 2003;60:92–9
255. Kisely S. Psychotherapy for severe personality disorder: exploring the limits of evi-
dence based purchasing. BMJ. 1999;318:1410–2.
256. Klein D.N., Schwartz J.E., Rose S., Leader J.B. Five-Year Course and Outcome of
Dysthymic Disorder: A Prospective, Naturalistic Follow-Up Study. Am J Psychiatry.
2000;157:931–9.
257. Krystal J.H., Rosenheck R.A., Cramer J.A. et al. Adjunctive Risperidone Treatment
for Antidepressant-Resistant Symptoms of Chronic Military Service-Related PTSD.
JAMA. 2011;306(5):493–502.
284
258. Kroenke K. Discovering Depression in Medical Patients: Reasonable Expectations.
Ann Intern Med. 1997;126:463–5.
259. Lessmeier T.J., Gamperling D., Johnson-Liddon V. et al. Unrecognized paroxysmal
supraventricular tachycardia: potential for misdiagnosis as panic disorder. Arch Intern
Med. 1997;157:537–43.
260. Li C.T., Bai Y.M., Huang Y.L. et al. Association between antidepressant resistance in
unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry.
2012;200(1):45–51.
261. Linehan M.M., Armstrong H.E., Suarez A. et al. Cognitive-behavioural treatment for
chronically parasuicidal borderline patients. Arch Gen Psychiatry. 1991;48:1060–4.
262. Linehan M.M., Heard H.L., Armstrong H.E. Interpersonal outcome of cognitive behav-
ioural treatment for chronically suicidal borderline patients. Am J Psychiatry.
1994;151:1771–6.
263. Licht–Strunk E., Van Marwijk H.W.J., Hoekstra T. et al. Outcome of depression in lat-
er life in primary care: longitudinal cohort study with three years' follow-up. BMJ.
2009;338:a3079.
264. Loerch B., Graf-Morgenstern M., Hautzinger M. et al. Randomised Placebo-
Controlled Trial of Moclobemide, Cognitive-Behavioural Therapy and Their Combination
in Panic Disorder With Agoraphobia. Br J Psychiatry. 1999;174:205–12.
265. Loui M., Jane S., Davi W. et al. The Aberfan disaster: 33-year follow-up of survivors.
Br J Psychiatry. 2003;182:532.
266. Luty S.E., Carter J.D., Mckenzie J.M. et al. Randomised controlled trial of interper-
sonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry.
2007;190:496–502.
267. Maj M., Starace F., Sartorius N. Mental Disorders in HIV Infection and AIDS. WHO
1993.
268. Maly R.C. Early recognition of chemical dependence. Prim Care. 1993;20(1):33–50.
269. Mason B.J., Quello S., Goodell V. et al. Gabapentin Treatment for Alcohol Depend-
ence: A Randomized Clinical Trial. JAMA Intern Med. 2014;174(1):70–7.
270. March J.S., Frances A., Kahn D.A., Carpenter D. The Expert Consensus Guideline
Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry. 1997;58 (suppl
4).
271. Marcus B.H., Albrecht A.E., King T.K. et al. The Efficacy of Exercise as an Aid for
Smoking Cessation in Women. A Randomized Controlled Trial. Arch Intern Med.
1999;159:1229–34.
272. Mason B.J., Salvato F.R., Williams L.D. et al. A Double-blind, Placebo-Controlled
Study of Oral Nalmefene for Alcohol Dependence. Arch Gen Psychiatry. 1999;56:719–
24.
273. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreat-
ment drinking outcomes. J Stud Alcohol. 1997;58:7–29.
274. Mayo-Smith M.F. Pharmacological management of alcohol withdrawal. A meta-
analysis and evidence-based practice guideline. JAMA. 1997;278:144–51.
275. McCrank E., Schurmans K., Lefcoe D. Paroxysmal Supraventricular Tachycardia
Misdiagnosed as Panic Disorder. Arch Intern Med. 1998;158:297.
276. McGrath P.J., Stewart J.W., Janal M.N. et al. A Placebo-Controlled Study of Fluoxe-
tine Versus Imipramine in the Acute Treatment of Atypical Depression. Am J Psychiatry.
2000;157:344–50.
277. Mead G.E., Morley W., Campbell P. et al. Exercise for depression. Cochrane
Database of Systematic Reviews 2009, Issue 3.
278. Mealer M.L., Shelton A., Berg B. et al. Increased Prevalence of Post-traumatic Stress
Disorder Symptoms in Critical Care Nurses. Am J Respir Crit Care Med. 2007;175:693–
7.
279. Melanie C., Nicola J.W., John C. et al. Facilitated physical activity as a treatment for
depressed adults: randomised controlled trial. BMJ 2012;344.
285
280. Merikangas K.E., Akiskal H.S., Angst J. et al. Lifetime and 12-month prevalence of
bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psy-
chiatry. 2007;64:543–52.
281. Meulenbeek P., Willemse G., Smit F. et al. Early intervention in panic: pragmatic ran-
domised controlled trial. Br J Psychiatry. 2010;196(4):326–31.
282. Minozzi S., Amato L., Vecchi S. et al. Oral naltrexone maintenance treatment for opi-
oid dependence. Cochrane Database of Systematic Reviews 2011, Issue 4.
283. Moore R.D., Bone L.R., Geller G. et al. Prevalence, detection, and treatment of alco-
holism in hospitalized patients. JAMA. 1989;261(3):403–7.
284. Moore T.J., Furberg C.D., Glenmullen J. et al. Suicidal behavior and depression in
smoking cessation treatments. PLoS One. 2011;6:e27016.
285. Morgan C.A., Hill S., Fox P. et al. Anniversary Reactions in Gulf War Veterans: A Fol-
low-Up Inquiry 6 Years After the War. Am J Psychiatry. 1999;156:1075–9.
286. Mortensen E.L., Jensen H.H., Sanders S.A., Reinisch J.M. Better Psychological
Functioning and Higher Social Status May Largely Explain the Apparent Health Benefits
of Wine. Arch Intern Med. 2001;161:1844–8.
287. Myric H., Anton R.F. Treatment of Alcohol Withdral. Alcohol Health&Research World.
1998;22:1:38–43.
288. National Institute for Health and Clinical Excellence. Obsessive-compulsive disorder:
Core interventions in the treatment of obsessive-compulsive disorder and body dys-
morphic disorder. 2006.
289. Ng M., Freeman M.K., Fleming T.D. et al. Smoking Prevalence and Cigarette Con-
sumption in 187 Countries, 1980-2012. JAMA. 2014;311(2):183–92.
290. NICE. Generalised anxiety disorder and panic disorder (with or without agoraphobia)
in adults. January 2011.
291. North C.S., Nixon S.J., Shariat S. et al. Psychiatric Disorders Among Survivors of the
Oklahoma City Bombing. JAMA. 1999;282:755–62.
292. North C.S., Pfefferbaum B. Mental Health Response to Community Disasters: A Sys-
tematic Review. JAMA. 2013;310(5):507–18.
293. Noyes R., Clancy J., Hoenk P.R., Slymen D.J. The prognosis of anxiety neurosis.
Arch Gen Psychiatry. 1980;37:173–8.
294. O'Neill B., Williams A.F., Dubowski K.M. Variability in blood alcohol concentrations.
Implications for estimating individual results. J Stud Alcohol. 1983;44:222–30.
295. Otto M.W., Pollack M.H., Penava S.J., Zucker B.G. Group Cognitive-Behavior Thera-
py for Patients Failing to Respond to Pharmacotherapy for Panic Disorder: A Clinical
Case Series. Behav Res Ther. 1999;37:763–70.
296. Ougrin D. Efficacy of Exposure versus Cognitive Therapy in Anxiety Disorders. BMC
Psychiatry. 2011;11(200).
297. Oxman T.E., Barrett J.E., Freeman D.H., Manheimer E. Frequency and correlates of
adjustment disorder related to cardiac surgery in older patients. Psychosomatics.
1994;35:557–68.
298. Papakostas G.I., Charles D., Fava M. Are typical starting doses of the selective
serotonin reuptake inhibitors sub-optimal? World J Biol Psychiatry. 2010;11(2 Pt 2):300–
7.
299. Parsons A.C., Shraim M., Inglis J. et al. Interventions for preventing weight gain after
smoking cessation. Cochrane Database of Systematic Reviews 2009, Issue 1.
300. Pearson T.A. Alcohol and heart disease. AHA Medical/Scientific Statement. Circula-
tion. 1996;94:3023–5.
301. Penninx B.W.J.H., Geerlings S.W., Deeg D.H.J. et al. Minor and Major Depression
and the Risk of Death in Older Persons. Arch Gen Psychiatry. 1999;56:889–95.
302. Pettinati H.M., Oslin D.W., Kampman K.M. et al. A Double-Blind, Placebo-Controlled
Trial Combining Sertraline and Naltrexone for Treating Co-Occurring Depression and Al-
cohol Dependence. Am J Psychiatry 2010;167(6):668–75.
303. Pharmacotherapy for Alcohol Dependence. Summary, Evidence Report/Technology
Assessment: Number 3, January 1999. Agency for Health Care Policy and Research.
286
304. Piper M.E., Smith S.S., Schlam T.R. et al. A Randomized Placebo-Controlled Clinical
Trial of 5 Smoking Cessation Pharmacotherapies. Arch Gen Psychiatry.
2009;66(11):1253–62.
305. Pollock K.M. Exercise in treating depression: Broadening the psychotherapist's role. J
Clin Psychol. 2001;57(11):1289–300.
306. Polosa R., Caponnetto P., Morjaria J.B. et al. Effect of an electronic nicotine delivery
device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot
study. BMC Public Health. 2011;11:786.
307. Prater C.D., Miller K.E., Zylstra R.G. Outpatient Detoxification of the Addicted or Al-
coholic Patient. Am Fam Physician. 1999;60:1175–83.
308. Rasmussen S.A., Tsuang M.T. Epidemiology of obsessive-compulsive disorder: a
review. J Clin Psych. 1984;45:450–7.
309. Reid M.C., Fiellin D.A., O'Connor P.G. Hazardous and Harmful Alcohol Consumption
in Primary Care. Arch Intern Med. 1999;159:1681–9.
310. Rickels K., Etemad B., Khalid-Khan S. et al. Time to Relapse After 6 and 12 Months'
Treatment of Generalized Anxiety Disorder With Venlafaxine Extended Release. Arch
Gen Psychiatry. 2010;67(12):1274–81.
311. Rimm E.B., Klatsky A., Groblee D., Stampter M.J. Review of moderate alcohol con-
sumption and reduced risk of coronary heart disease: is the effect due to beer,wine or
spirits? BMJ. 1996;312:731–7.
312. Rinne T., van den Brink W., Wouters L. et al. SSRI Treatment of Borderline Personali-
ty Disorder: A Randomized, Placebo-Controlled Clinical Trial for Female Patients With
Borderline Personality Disorder. Am J Psychiatry. 2002;159:2048–54.
313. Roberts N.P., Kitchiner N.J., Kenardy J., Bisson J. Multiple session early psychologi-
cal interventions for the prevention of post-traumatic stress disorder. Cochrane Database
of Systematic Reviews 2009, Issue 3.
314. Robins L., Helzer J., Weissman M. et al. Lifetime prevelance of specific psychiatric
disorders in three sites. Archives in General Psychiatry. 1984;138:949–58.
315. Rose S., Bisson J., Churchill R., Wessely S. Psychological debriefing for preventing
post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2002,
Issue 2.
316. Rosner S., Hackl-Herrwerth A., Leucht S. et al. Acamprosate for alcohol dependence.
Cochrane Database of Systematic Reviews 2010, Issue 9.
317. Roy-Byrne P.P., Cowley D.S. Course and outcome in panic disorder: a review recent
follow-up studies. Anxiety. 1995;1:150–60.
318. Rush A.J., Trivedi M.H. Treating depression to remission. Psychiatric Annals.
1995;25:704–9.
319. Ryle A. Cognitive-analytical therapy: active participation in change. Chichester: John
Wiley, 1990.
320. Savino M., Perugi G., Simonini E et al. Affective comorbidity in panic disorder: is there
a bipolar connection? J Affect Disord. 1993;28:155–63.
321. Schneier F.R., Johnson J., Hornig C.D. et al Social phobia: comorbidity and morbidity
in an epidemiologic sample. Arch Gen Psychiatry. 1992;49:282–8.
322. Schneier F.R. Social Anxiety Disorder. N Engl J Med. 2006;355:1029–36.
323. Schnyder U., Moergeli H., Klaghofer R., Buddeberg C. Incidence and Prediction of
Posttraumatic Stress Disorder Symptoms in Severely Injured Accident Victims. Am J
Psychiatry. 2001;158:594–9.
324. Segal Z.V., Bieling P., Young T. et al. Antidepressant Monotherapy vs Sequential
Pharmacotherapy and Mindfulness-Based Cognitive Therapy, or Placebo, for Relapse
Prophylaxis in Recurrent Depression. Arch Gen Psychiatry. 2010;67(12):1256–64.
325. Sheehan D.V. Current perspectives in the treatment of panic and phobic disorders.
Drug Ther. 1982;12(9):179–93.
326. Silver R.C., Holman E.A., McIntosh D.N. et al. Nationwide Longitudinal Study of Psy-
chological Responses to September 11. JAMA. 2002;288:1235–44.
287
327. Singh S., Loke Y.K., Spangler J.G. et al. Risk of serious adverse cardiovascular
events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011.
328. Single E., Robson L., Xie X., Rehm J. The economic costs of alcohol, tobacco and
illicit drugs in Canada, 1992. Addiction. 1998;93:991–1006.
329. Skodol A.E., Oldham J.M., Gallaher P.E. Axis II Comorbidity of Substance Use Disor-
ders Among Patients Referred for Treatment of Personality Disorders. Am J Psychiatry.
1999;156:733–8.
330. Skoog G., Skoog I. A 40-Year Follow-up of Patients With Obsessive-compulsive Dis-
order. Arch Gen Psychiatry. 1999;56:121–7.
331. Smith T.C., Ryan M.A.K.,Wingard D.L. et al. New onset and persistent symptoms of
post-traumatic stress disorder self reported after deployment and combat exposures:
prospective population based US military cohort study. BMJ. 2008;336:366–71.
332. Smith S.S., McCarthy D.E., Japuntich S.J. et al. Comparative Effectiveness of 5
Smoking Cessation Pharmacotherapies in Primary Care Clinics. Arch Intern Med.
2009;169(22):2148–55.
333. Sonis J., Gibson J.L., de Jong J.T.V.M. et al. Probable Posttraumatic Stress Disorder
and Disability in Cambodia: Associations With Perceived Justice, Desire for Revenge,
and Attitudes Toward the Khmer Rouge Trials. JAMA. 2009;302(5):527–36.
334. Stein M.B. Social anxiety disorder. Lancet. 2008; 371:1115–25.
335. Stein J. Minimize weight gain to maximize smoking-cessation benefit. American Col-
lege of Cardiology 2013 Scientific Sessions. http://www.theheart.org/article/1517161.do.
336. Tonnesen P., Paoletti P., Gustavsson G. et al. Higher Dosage Nicotine Patches In-
crease One-Year Smoking Cessation Rates: Results From the European CEASE Trial.
Collaborative European Anti-Smoking Evaluation. Eur Respir J. 1999;13(2):238–46.
337. Treatment of Depression: Newer Pharmacotherapies. Evidence Report/ Technology
Assessment No 7. Rockville, MD: Agency for Health Care Policy and Research; Febru-
ary 1999. AHCPR Publication No. 99–E014.
338. Tondo L., Isacsson G., Baldessarini R. Suicidal behaviour in bipolar disorder: risk and
preventions. CNS Drugs. 2003; 17:491–511.
339. Valenstein M. Antidepressants do Not Reduce Symptoms or Failure to Respond
Compared With Placebo in Minor Depression. Evid Based Ment Health. 2011;14(4).
340. Vilhelmsson A., Svensson T., Meeuwisse A., Carlsten A. What can we learn from
consumer reports on psychiatric adverse drug reactions with antidepressant medication?
Experiences from reports to a consumer association. BMC Clin Pharmacol. 2011;11:16.
341. Wald N.J., Watt H.C. Procpective study of effect of switching from cigarettes to pipes
or cigars on mortality from three smoking related diseases. BMJ. 1997;314:1860–3.
342. Weissman M.M., Bland R.C., Canino G.J. et al. The cross national epidemiology of
obsessive compulsive disorder. The Cross National Collaborative Group. J Clin
Psychiatry. 1994;55 Suppl:5–10.
343. World Health Organization. Guidelines for the Management of Conditions Specifically
Related to Stress. 2013. 267 p.
344. Wiese J.G., Shlipak M.G., Browner W.S. The Alcohol Hangover. Ann Intern Med.
2000;132:897–902.
345. WHO. Global Status Report on Alcohol 2004.
346. Whooley M.A., Boyd A.L., Gardin J.M., Williams D.R. Religious Involvement and Cig-
arette Smoking in Young Adults. Arch Intern Med. 2002;162:1604–10.
347. Wiles N.J., Mulligan J., Peters T.J. et al. Severity of depression and response to
antidepressants: GENPOD randomised controlled trial. Br J Psychiatry.
2012;200(2):130–6.
348. Xie P, Kranzler HR, Poling J, et al. Interactive Effect of Stressful Life Events and the
Serotonin Transporter 5-HTTLPR Genotype on Posttraumatic Stress Disorder Diagnosis
in 2 Independent Populations. Arch Gen Psychiatry. 2009;66(11):1201–9.
349. Zhang Y., Guo X., Saitz R. et al. Secular Trends in Alcohol Consumption over 50
Years: The Framingham Study. Am J Med. 2008;121:695–701.
288
350. Zerbe K.J., Steinberg D.L. Coming to terms with grief and loss: can skills for dealing
with bereavement be learned? Postgrad Med. 2000;108(6):97–106.
Глава 3
1. Абхольц Х.Х., Безель К., Бени Р. Общепрактическая и семейная медицина. Пер. с
нем. Минск: Беларусь; 1997. 620 c.
2. Белялов Ф.И. Лечение внутренних болезней в условиях коморбидности. Иркутск:
РИО ИГИУВа, 2012. 286 с.
3. Губачев Ю.М, Стабровский Е.М. Клинико-физиологические основы психосоматиче-
ских соотношений. М: Медицина; 1981. 216 с.
4. Ибатов А. Д. Влияние тревожных
расстройств на течение ишемической болезни
сердца. РМЖ. 2007;15(20):1443–6.
5. Лисицына Т.А., Вельтищев Д.Ю., Серавина О.Ф. и др. Варианты психических нару-
шений у больных системной красной волчанкой. Научно-практич. ревматология
2008;4:21–6.
6. Мальцева Л.Е., Ягудина Р.Н. Выраженность стенокардии и психическое состояние.
В кн.: Кардиологическая наука и практика 2009: материалы конференции
, 12 нояб-
ря 2009 года, Иркутск. Под ред. Ф.И.Белялова. Иркутск, 2009. с. 17–9.
7. Организационная модель помощи лицам, страдающим депрессиями, в условиях
территориальной поликлиники. Методические рекомендации. М; 2000.
8. Променашева Т.Е., Чайкисов Ю.С., Мальцева Л.Е. Клинико-функциональные связи
артериальной гипертензии и психических факторов. В кн.: Сочетанные заболева-
ния внутренних органов в
терапевтической практике: материалы II конференции, 15
мая 2008 года, Иркутск. Под ред. Ф.И.Белялова. Иркутск, 2008. с. 14–5.
9. Смулевич А.Б. Депрессии в общемедицинской практике. М: Берег; 2000. 160 с.
10. Смулевич А.Б, Сыркин А.Л. Психокардиология. М: МИА; 2005. 784 с.
11. Собенников В.С., Белялов Ф.И. Соматизация и психосоматические расстройства.
Иркутск: РИО ИГИУВа, 2010. 231 с.
12. Aadil N., Houti I.E., Moussamih S. Drug intake during Ramadan. BMJ. 2004;
329(7469):778–82.
13. AAFP. Post-Myocardial Infarction Depression Clinical Practice Guideline Panel. AAFP
Guideline for the Detection and Management of Post-Myocardial Infarction Depression.
Ann Fam Med. 2009;7(1):71–9.
14. Abas M., Hotopf M., Prince M. Depression and mortality in a high-risk population: II-Year
follow-up of the Medical Research Council Elderly Hypertension Trial. Br J Psychiatry.
2002;181(2):123–8.
15. Abramson J., Berger A., Krumholz H.M., Vaccarino V. Depression and Risk of Heart
Failure Among Older Persons With Isolated Systolic Hypertension. Arch Intern Med.
2001;161:1725–30.
16. Abrams T.E., Vaughan-Sarrazin M., Vander Weg M.W. Acute Exacerbations of Chronic
Obstructive Pulmonary Disease and the Effect of Existing Psychiatric Comorbidity on
Subsequent Mortality. Psychosomatics. 2011;52[5]:441–9.
17. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-
segment elevation myocardial infarction: a report of the ACC/AHA Task Force on Prac-
tice Guidelines. J Am Coll Cardiol. 2000;36:970–1062.
18. Achar E., Maciel T.T, Collares C.F. et al. Amitriptyline attenuates interstitial inflammation
and ameliorates the progression of renal fibrosis. Kidney International. 2009;75:596–604
19. Adams R.J., Wilson D.H., Taylor A.W. et al. Psychological factors and asthma quality of
life: a population based study. Thorax. 2004;59:930–5.
20. Adams J., Kuchibhatla M., Christopher E.J. et al. Association of Depression and Survival
in Patients with Chronic Heart Failure over 12 Years. Psychosomatics. 2012;53[4]:339–
346.
21. Agatisa P.K., Matthews K.A., Bromberger J.T. et al. Coronary and Aortic Calcification in
Women With a History of Major Depression. Arch Intern Med. 2005;165:1229–36.
289
22. Agreus L., Talley N. Challenges in managing dyspepsia in general practice. BMJ.
1997;315:1284–8.
23. Ahmadi N., Hajsadeghi F., Mirshkarlo H.B. et al. Post-traumatic Stress Disorder, Coro-
nary Atherosclerosis, and Mortality. The American journal of cardiology. 2011;108:29–33.
24. Ahmedani B.K., Peterson E.L., Wells K.E. et al. Examining the Relationship Between
Depression and Asthma Exacerbations in a Prospective Follow-Up Study. Psychosom
Med. 2013;75 (3):305–10.
25. Aikens J.E. Prospective Associations Between Emotional Distress and Poor Outcomes in
Type 2 Diabetes. Diabetes Care. 2012;35(12):2472–8.
26. Akechi T., Okamura H., Yamawaki S. et al. Why Do Some Cancer Patients With Depres-
sion Desire an Early Death and Others Do Not? Psychosomatics. 2001;42:141–5.
27. Al Badarin F.J., Spertus J.A., Gosch K.L. et al. Initiation of statin therapy after acute my-
ocardial infarction is not associated with worsening depressive symptoms. American
heart journal. 2013;879–86.
28. Alao A.O., Chlebowski S., Chung C. Neuropsychiatric Systemic Lupus Erythematosus
Presenting as Bipolar I Disorder With Catatonic Features. Psychosomatics.
2009;50(5):543–7.
29. Albers J.M., Kuper H.H., van Riel P.L. et al. Socio-economic consequences of rheuma-
toid arthritis in the first years of the disease. Rheumatology. 1999;38(5):423–30.
30. Albert C.M., Chae C.U., Rexrode K.M. et al. Phobic Anxiety and Risk of Coronary Heart
Disease and Sudden Cardiac Death Among Women. Circulation. 2005;111:480–7.
31. Albert N.M., Fonarow G.C., Abraham W.T. et al. Depression and Clinical Outcomes in
Heart Failure: An OPTIMIZE-HF Analysis. Am J Med. 2009;122:366–73.
32. Albus C., Jordan J., Herrmann-Lingen C. Screening for psychosocial risk factors in pa-
tients with coronary heart disease-recommendations for clinical practice. Eur J Cardio-
vasc Prev Rehabil. 2004;11(1):75–9.
33. Alexopoulos G.S., Meyers B.S., Young R.C. et al. Clinically defined vascular depression.
Am J Psychiatry. 1997; 154:562–5.
34. Alexopoulos G.S., Meyers B.S., Young R.C. et al. 'Vascular depression' hypothesis. Arch
Gen Psychiatry. 1997;54(10):915–22.
35. Allan L.M., Rowan E.N., Thomas A.J. et al. Long-term incidence of depression and pre-
dictors of depressive symptoms in older stroke survivors. The British Journal of
Psychiatry. 2013;203(6):453–60.
36. Almanza J., Holland J.C., Breitbart W.S. Psychiatric Disorders in 620 Referrals to the
Memorial Sloan-Kettering Counseling Center. Psychosomatics. 2000;41:157–90.
37. Almeida C., Brasil M.A., Costa A.J. et al. Subclinical hypothyroidism: psychiatric
disorders and symptoms. Rev Bras Psiquiatr. 2007;29(2):157–9.
38. Almeida O.P., Calver J., Jamrozik K. et al. Obesity and metabolic syndrome increase the
risk of incident depression in older men: the health in men study. Am J Geriatr Psychia-
try. 2009;17(10):889–98.
39. Almeida O.P., Alfonso H., Flicker L. et al. Thyroid Hormones and Depression: The Health
In Men Study. American Journal of Geriatric Psych 2011;19(9).
40. Alosco M.L., Spitznagel M.B., Raz N. et al. The Interactive Effects of Cerebral Perfusion
and Depression on Cognitive Function in Older Adults With Heart Failure. Psychosom
Med. 2013;75(7):632–9.
41. American Psychiatric Association. Treatment of Patients With Major Depressive Disor-
der. 2010.
42. Ambardekar A.V., Fonarow G.C., Hernandez A.F. et al. Characteristics and in-hospital
outcomes for nonadherent patients with heart failure: findings from Get With The Guide-
lines-Heart Failure (GWTG-HF). Am Heart J. 2009;158(4):644–52.
43. Andersen H.L. On the Effect of Unemployment on Mortality. iHEA 2007 6th World Con-
gress, June 18, 2007.
44. Anderson R.J., Gott B.M., Sayuk G.S. et al. Antidepressant Pharmacotherapy in Adults
With Type 2 Diabetes. Diabetes Care. 2010;33(3):485–9.
Соседние файлы в папке Библиотека им академика М.И. Перельмана